Chemotherapy in ca urinary bladder dr prasanta dash
Reolysin
CK 193-2594-2-PB
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) Eric Van Cutsem, MD, PhD University Hospitals Gasthuisberg/Leuven, Leuven,
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 Cells) Have Long-Term Persistence and Induce Durable Responses in Relapsed, Refractory.
RECIST Overview. Introduction What is RECIST? RECIST Endpoints in Berenice Definitions Methods of Assessment Schedule of Assessments Evaluation.
Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy 1 Final.
1 Coiffier B et al. J Clin Oncol 2012;30(6):631-6 . Proc ASH 2011;Abstract 591.
bliss_01_0311
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer ( mCRC )
